| Literature DB >> 28854218 |
Lingmei Sun1, Kai Liao2, Dayong Wang3.
Abstract
BACKGROUND: Honokiol, a compound extracted from Magnolia officinalis, has antifungal activities by inducing mitochondrial dysfunction and triggering apoptosis in Candida albicans. However, the mechanism of honokiol-induced oxidative stress is poorly understood. The present investigation was designed to determine the specific mitochondrial reactive oxygen species (ROS)-generation component. METHODS/Entities:
Mesh:
Substances:
Year: 2017 PMID: 28854218 PMCID: PMC5576747 DOI: 10.1371/journal.pone.0184003
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Levels of HO (A) and O(B) in (A) and (B) ROS production was evaluated by flow cytometry. (C) The percentage of ROS-positive cells after honokiol treatment. H2O2 and O2•− were determined by fluorometric detection of the oxidation products of DCFH-DA and DHE, respectively. **p<0.01.
Fig 2Effect of rotenone on C. albicans survival and ROS production after honokiol treatment.
(A) Effect of rotenone on C. albicans survival after honokiol treatment. The SC5314 cells were treated with rotenone at concentrations of 0.156mM or 0.31mM for 1h and then exposed to honokiol for 24h. Effect of rotenone on H2O2 (B) and O2•−(C) production after honokiol treatment. ROS production was evaluated by flow cytometry as described in Materials and Methods. **p<0.01.
Fig 3Effect of other mitochondrial respiratory chain inhibitors on C. albicans survival and ROS production after honokiol treatment.
(A) Effect of respiratory chain inhibitors on C. albicans survival after honokiol treatment. The SC5314 cells were treated with respiratory chain inhibitors for 1h and then exposed to honokiol for 24h. (B) Effect of respiratory chain inhibitors on O2•− production after honokiol treatment. O2•− production was evaluated by flow cytometry as described in Materials and Methods. TTFA, thenoyltrifluoroacetone (0.125mM); menadione (0.0625mM); NaN3 (0.0025%); Sham, salicylhydroxamic acid (5mM); oligomycin (5μg/ml).
Fig 4Effect of honokiol on respiratory activity and C I enzyme activity in C. albicans.
(A) C. albicans SC5314 stained with CTC. (B) The relative fluorescence intensity was obtained by flow cytometric analysis of CTF-stained cells. (C) Effect of honokiol on C I enzyme activity. Scale bar = 10μm. **p<0.01.
Fig 5The effect of honokiol on mtDNA in C. albicans.
(A) Nuclear and mtDNA was stained with DAPI. Nuclear DNA stained brightly, while the mitochondrial nucleoids displayed punctuate cytoplasmic staining. N, nucleus; M, mtDNA. (B) qRT-PCR analyzed the expression of mtDNA genes. Expression is relative to control group and the data are presented as the average of three biological replicates each normalized to ACT1. **p<0.01.
Fig 6Honokiol treatment increases the sensitivity to cell wall-perturbing agents against C. albicans.
(A) Honokiol treatment increases the sensitivity to Congo red. (B) Honokiol treatment increases the sensitivity to SDS. Cells were treated with honokiol (4μg/mL), cell-wall perturbing agents (Congo red, 4μg/mL; SDS, 0.01%) or their combination for 24 h. Viability detections were described in Materials and Methods. **p<0.01.
Fig 7Transcriptional profiling of mitochondrial electron transport (A) and oxidation-reduction process (B) in The expression level of genes which are represented by log2 (RPKM) values are indicated from blue to red.
Fig 8Transcriptional profiling of genes in response to honokiol treatment.
Functional annotation for genes are shown: (A) genes of mitochondrial transporter, mitochondrion localization, mitochondrial membrane protein, and mitochondrial ribosomal protein. (B) genes involved in carbon metabolism, such as glycolysis, TAC cycles, and glyoxylate cycle. (C) genes involved in cell wall. The expression level of genes which are represented by log2 (RPKM) values are indicated from blue to red.
GO enrichment analysis.
| Term | TermName | DEGs number | Gene name | Padj | |||
|---|---|---|---|---|---|---|---|
| Ontology: Biological process | |||||||
| GO:0042254 | ribosome biogenesis | 31 | orf19.5991,RRS1,NOC4,orf19.6234,UTP21,DIM1,SPB4,YTM1,NOG1,KRR1,orf19.6828,IMP4,DBP8,RPS8A,HCA4,UBI3,orf19.1646,PES1,MRT4,NSA1,YST1,orf19.3393,NEP1,RCL1,TSR1,NOP5,RPL8B,RPL82,orf19.3778,GAR1,orf19.1388 | 0.00578 | |||
| GO:0042775 | mitochondrial ATP synthesis coupled electron transport | 14 | CaalfMp11.1,COX1,CaalfMp08.4,CaalfMp08.1,COB,NAD4L,NAD1,NAD4,CaalfMp08.2,COX2,NAD5,NAD2,NAD6,CaalfMp08.3 | 0.00604 | |||
| GO:0006119 | oxidative phosphorylation | 14 | NAD6,CaalfMp08.3,COX2,CaalfMp08.2,NAD5,NAD2,NAD4L,NAD1,NAD4,CaalfMp11.1,COX1,CaalfMp08.1,CaalfMp08.4,COB | 0.01208 | |||
| GO:0042773 | ATP synthesis coupled electron transport | 14 | NAD5,NAD2,CaalfMp08.2,COX2,CaalfMp08.3,NAD6,CaalfMp08.4,CaalfMp08.1,COB,CaalfMp11.1,COX1,NAD4,NAD1,NAD4L | 0.01208 | |||
| GO:0022904 | respiratory electron transport chain | 14 | CaalfMp08.3,NAD6,NAD5,NAD2,CaalfMp08.2,COX2,NAD4,NAD1,NAD4L,CaalfMp08.1,COB,CaalfMp08.4,CaalfMp11.1,COX1 | 0.04127 | |||
| Ontology: Molecular function | |||||||
| GO:0016491 | oxidoreductase activity | 111 | XYL2,NAD4L,OYE22,orf19.3706,ADH4,FET99,DLD2,orf19.6518,orf19.7288,CaalfMp11.1,CaalfMp08.1,ADH3,PXP2,orf19.7306,EBP7,orf19.1366,SSP96,orf19.5565,orf19.2175,MXR1,IFM3,orf19.1639,NAD4,OYE23,orf19.2782,orf19.1438,orf19.5728,orf19.1340,orf19.2312,AOX2,YIM1,POX1,NAD2,GDH3,GPD2,SOD6,orf19.6066,IFD3,orf19.4567,spliced|Uncharacterized,orf19.2177,orf19.1844,orf19.86,FRE7,POX18,PRX1,NAD1,RNR1,orf19.1461,ERO1,RNR22,ERV1,TRX1,orf19.6341,NAD6,CFL2,orf19.1802,CFL4,GRP2,orf19.7204,FMO1,GRE2,FOX2,IFD6,ARG5,6,FET34,ADH2,orf19.4476,COB,HOM2,SOD5,orf19.5978,orf19.320,MIA40,orf19.7364,CaalfMp08.2,FRE9,orf19.6838,NAD5,TTR1,COX6,orf19.355,FRE30,orf19.5879,orf19.3537,orf19.1709,COX2,PUT2,ALK2,IFK2,orf19.6869,orf19.6306,COX1,CaalfMp08.4,CaalfMp08.3,orf19.3711,orf19.2394,MDH1-3,orf19.6398,GDH2,YMX6,orf19.2197,orf19.5655,TSA1,orf19.7495,orf19.2244,orf19.22.1,orf19.6143,orf19.6758,orf19.3292,ALK8 | 0.00949 | |||
| Ontology: Cellular component | |||||||
| GO:0005746 | mitochondrial respiratory chain | 14 | CaalfMp08.3,NAD6,NAD5,NAD2,CaalfMp08.2,COX2,NAD4,NAD1,NAD4L,CaalfMp08.4,CaalfMp08.1,COB,CaalfMp11.1,COX1 | 0.00149 | |||
| GO:0000502 | proteasome complex | 18 | orf19.6973,orf19.213,RPT2,PUP2,orf19.1993,PRE8,RPN2,RPN3,PUP3,ECM29,RPN1,RPN10,PRE9,PRE10,orf19.2755,orf19.5961,CIC1,orf19.2301 | 0.00854 | |||
| GO:0070469 | respiratory chain | 15 | NAD1,NAD4L,NAD4,COX1,CaalfMp11.1,CaalfMp08.1,AOX2,CaalfMp08.4,COB,NAD6,CaalfMp08.3,CaalfMp08.2,COX2,NAD2,NAD5 | 0.0169 | |||
aSignificantly enriched representative GO terms (adjusted p-value<0.05) are listed in table.
Fig 9KEGG pathway annotation in response to honokiol treatment.
The bottom x-axis indicates he main category. The y-axis indicates the number of genes in a specific category. The results are summarized in the following four main categories: (1) metabolism;(2) genetic information processing; (3) cellular precesses; (4) environmental information processing.
Fig 10A model of the cellular response to honokiol treatment.
Honokiol targets on the mitochondrial respiratory electron transport chain C I inducing ROS production (mainly O2·−) and mitochondria dysfunction. ROS induces mtDNA damage, mtΔψ decrease, oxidation of proteins and lipids. The transcriptome indicates that the cellular stress response increases including increased protein import to mitochondria, upregulate the expression of antioxidant enzyme genes, remove oxidized proteins by the ubiquitin-dependent proteasome system. Mitochondrial dysfunction in C. albicans is associated with loss of cell wall integrity. (1) affect the activity of wall synthesis enzymes in plasma membrane; (2) impinge on GPI anchor synthesis; (3)activation of cell wall integrity pathway upon cell wall stress. mtΔψ: mitochondrial membrane potential.